🧠 TL;DR Nivolumab is a PD-1 immunotherapy that activates your immune system against cancer Used in lung, head & neck, esophagus, melanoma, kidney, lymphoma, colorectal (MSI-high) Long-acting (~26 days) → small delays are usually safe Side effects are immune-related (not infection-related) Timing of side effects gives major diagnostic clues Can be used safely in kidney failure, dialysis, liver dysfunction (non-immune) Cost in India has dropped from ₹4.5 lakh → ~₹1 lakh/month

Immunotherapy is one of the biggest advancements in cancer treatment today. One of the most commonly used drugs is Pembrolizumab (Keytruda). But a very important question patients ask is:👉 “Is this treatment safe for me, and how do I take it correctly?” Immunotherapy is powerful, but only when used in the right patient, at the right time, with the right monitoring. TL;DR Pembrolizumab works by activating your immune system to fight cancer by removing the “brakes” that cancer

CAR-T cell therapy represents a breakthrough immunotherapy for relapsed and refractory blood cancers, now accessible in India at a fraction of global costs, making advanced cancer treatment available to patients who previously had limited options. TL;DR India's CAR-T cell therapy costs Rs 30-40 lakhs compared to Rs 3-4 crore internationally, representing 90% savings for patients [2] Indigenous therapies like NexCAR19 have demonstrated a 70% overall response rate in clinical t